Mondragón-Rodríguez Siddhartha, Basurto-Islas Gustavo, Santa-Maria Ismael, Mena Raúl, Binder Lester I, Avila Jesús, Smith Mark A, Perry George, García-Sierra Francisco
Department of Cell Biology, CINVESTAV-IPN, México City, México.
Int J Exp Pathol. 2008 Apr;89(2):81-90. doi: 10.1111/j.1365-2613.2007.00568.x.
Phosphorylation, cleavage and conformational changes in tau protein all play pivotal roles during Alzheimer's disease (AD). In an effort to determine the chronological sequence of these changes, in this study, using confocal microscopy, we compared phosphorylation at several sites (Ser(199/202/396/404/422)-Thr(205) and the second repeat domain), cleavage of tau (D(421)) and the canonical conformational Alz-50 epitope. While all of these posttranslational modifications are found in neurofibrillary tangles (NFTs) at all stages of the disease, we found significantly higher numbers of phospho-tau positive NFTs when compared with cleaved tau (P = 0.006 in Braak III; P = 0.002 in Braak IV; P = 0.012 in Braak V) or compared with the Alz-50 epitope (P < 0.05). Consistent with these findings, in a double transgenic mice model (Tet/GSK-3beta/VLW) overexpressing the enzyme glycogen synthase kinase-3beta (GSK-3beta) and tau with a triple FTDP-17 mutation (VLW) with AD-like neurodegeneration, phosphorylation at sites Ser(199/202)-Thr(205) was greater than truncated tau. Taken together, these data strongly support the notion that the conformational changes and truncation of tau occur after the phosphorylation of tau. We propose two probable pathways for the pathological processing of tau protein during AD, either phosphorylation and cleavage of tau followed by the Alz-50 conformational change or phosphorylation followed by the conformational change and cleavage as the last step.
tau蛋白的磷酸化、裂解和构象变化在阿尔茨海默病(AD)过程中均起着关键作用。为了确定这些变化的时间顺序,在本研究中,我们使用共聚焦显微镜比较了tau蛋白多个位点(Ser(199/202/396/404/422)-Thr(205)以及第二个重复结构域)的磷酸化、tau蛋白的裂解(D(421))和典型的构象性Alz-50表位。虽然所有这些翻译后修饰在疾病的各个阶段均存在于神经原纤维缠结(NFTs)中,但我们发现,与裂解的tau蛋白相比(Braak III期P = 0.006;Braak IV期P = 0.002;Braak V期P = 0.012),或与Alz-50表位相比(P < 0.05),磷酸化tau蛋白阳性的NFTs数量显著更多。与这些发现一致,在一个双转基因小鼠模型(Tet/GSK-3β/VLW)中,该模型过表达糖原合酶激酶-3β(GSK-3β)以及带有三联体FTDP-17突变(VLW)且具有AD样神经退行性变的tau蛋白,Ser(199/202)-Thr(205)位点的磷酸化程度高于截短的tau蛋白。综上所述,这些数据有力地支持了tau蛋白的构象变化和截短发生在tau蛋白磷酸化之后这一观点。我们提出了AD期间tau蛋白病理加工的两条可能途径,即tau蛋白先磷酸化和裂解,随后发生Alz-50构象变化;或者先磷酸化,随后发生构象变化,最后一步是裂解。